-
公开(公告)号：US20190284135A1
公开(公告)日：2019-09-19
申请号：US16421006
申请日：2019-05-23
Applicant: AbbVie Inc.
Inventor： Dominique Bonafoux , Heather Michele Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep Kaur Somal , Jennifer Van Camp , Stacy Anne Van Epps , Anil Vasudevan , Grier Allan Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D209/08 , C07D487/04 , C07D405/14 , C07D231/56 , C07D403/14 , C07D401/14 , C07D417/14 , C07D471/04 , C07D417/12 , A61P35/00 , C07D513/04 , C07D209/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D209/10 , C07D209/12 , C07D413/04 , C07D209/18 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D401/12
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
公开(公告)号：US09163007B2
公开(公告)日：2015-10-20
申请号：US14136359
申请日：2013-12-20
Applicant: AbbVie Inc.
Inventor： Irini Akritopoulou-Zanze , Brian D. Wakefield , Helmut Mack , Sean C. Turner , Alan F. Gasiecki , Vijaya J. Gracias , Kathy A. Sarris , Douglas M. Kalvin , Melissa J. Michmerhuizen , Qi Shuai , Jyoti R. Patel , Margaretha H. M. Bakker , Nicole Teusch , Eric F. Johnson , Peter J. Kovar , Stevan W. Djuric , Andrew J. Long , Anil Vasudevan , Dawn M. George , Lu Wang , Biqin Li , Nigel S. Moore , Adrian D. Hobson , Keith W. Woods , Julie M. Miyashiro , Steven L. Swann, Jr. , Thomas D. Penning
IPC: C07D413/04 , C07D471/04 , C07D487/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D513/04
CPC classification number: C07D413/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶例如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT ，PAK4，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。
-
公开(公告)号：US20150210708A1
公开(公告)日：2015-07-30
申请号：US14610119
申请日：2015-01-30
Applicant: AbbVie Inc.
Inventor： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC: C07D487/14
CPC classification number: C07D487/14 , C07D498/14 , C07D513/14
Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号：US20140343066A1
公开(公告)日：2014-11-20
申请号：US14136359
申请日：2013-12-20
Applicant: AbbVie Inc.
Inventor： Irini Akritopoulou-Zanze , Brian D. Wakefield , Helmut Mack , Sean C. Turner , Alan F. Gasiecki , Vijaya J. Gracias , Kathy A. Sarris , Douglas M. Kalvin , Melissa J. Michmerhuizen , Qi Shuai , Jyoti R. Patel , Margaretha H.M. Bakker , Nicole Teusch , Eric F. Johnson , Peter J. Kovar , Stevan W. Djuric , Andrew J. Long , Anil Vasudevan , Dawn M. George , Lu Wang , Biqin Li , Nigel S. Moore , Adrian D. Hobson , Keith W. Woods , Julie M. Miyashiro , Steven L. Swann, Jr. , Thomas D. Penning
IPC: C07D413/04 , C07D471/04 , C07D487/04 , C07D513/04
CPC classification number: C07D413/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶例如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT ，PAK4，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。
-
公开(公告)号：US20210015938A1
公开(公告)日：2021-01-21
申请号：US16945069
申请日：2020-07-31
Applicant: AbbVie Inc.
Inventor： Adrian D. Hobson , Michael J. McPherson , Wendy Waegell , Christian Goess , Axel Hernandez, Jr. , Lu Wang , Lu Wang , Christopher C. Marvin , Ling C. Santora
Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
-
Patent Agency Ranking
公开(公告)号：US20170174624A1
公开(公告)日：2017-06-22
申请号：US15398978
申请日：2017-01-05
Applicant: AbbVie Inc.
Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D209/08 , C07D405/14 , C07D403/04 , C07D401/04 , C07D209/18 , C07D405/04 , C07D209/12 , C07D209/10 , C07D209/14 , C07D417/14 , C07D401/14 , C07D409/14 , C07D403/10 , C07D409/04 , C07D409/12 , C07D403/14 , C07D413/04
CPC classification number: C07D209/08 , A61P35/00 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
公开(公告)号：US09365579B2
公开(公告)日：2016-06-14
申请号：US14610119
申请日：2015-01-30
Applicant: AbbVie Inc.
Inventor： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC: C07D487/14 , C07D498/14 , C07D513/14
CPC classification number: C07D487/14 , C07D498/14 , C07D513/14
Abstract: The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫和肿瘤病症。
-
公开(公告)号：US20150005279A1
公开(公告)日：2015-01-01
申请号：US14315504
申请日：2014-06-26
Applicant: ABBVIE INC.
Inventor： Dominique Bonafoux , Heather M. Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep K. Somal , Jennifer Van Camp , Stacy A. Van Epps , Anil Vasudevan , Grier A. Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC: C07D487/04 , C07D471/04 , C07D209/08 , C07D401/12 , C07D401/14 , C07D403/14 , C07D231/56 , C07D417/12 , C07D417/14
CPC classification number: C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号：US10772970B2
公开(公告)日：2020-09-15
申请号：US16204825
申请日：2018-11-29
Applicant: AbbVie Inc.
Inventor： Adrian Hobson , Michael McPherson , Wendy Waegell , Christian Goess , Axel Hernandez, Jr. , Lu Wang , Lu Wang , Christopher C. Marvin , Ling C. Santora
Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
-
公开(公告)号：US20190167804A1
公开(公告)日：2019-06-06
申请号：US16204825
申请日：2018-11-29
Applicant: AbbVie Inc.
Inventor： Adrian Hobson , Michael McPherson , Wendy Waegell , Christian Goess , Axel Hernandez, JR. , Lu Wang , Lu Wang , Christopher C. Marvin , Ling C. Santora
Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.043 seconds)
